TRCT
ORIA

Tower Research Capital (TRC)’s Orion Biotech Opportunities Corp. Class A Ordinary Share ORIA Stock Holding History

Tower Research Capital (TRC)’s Portfolio ORIA Stock Details ORIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2
Closed – – 6900
2021
Q4 		$0 Buy
+2
New +$20 ﹤0.01% 6815

Other funds holding ORIA

6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
SCC
Spring Creek Capital Wichita, Kansas $2.53B AUM 19.59% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return
ACM
Atalaya Capital Management New York $45M AUM 3.02% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Tower Research Capital (TRC)'s ORIA Position: Q1 2022 in Review

Tower Research Capital (TRC) sold out of Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) in Q1 2022, closing a stake of 2 shares.

Tower Research Capital (TRC) first reported a position in ORIA in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 40 funds tracked by Wall St. Rank hold ORIA as of Q1 2022.

  • Tower Research Capital (TRC) reported no remaining Orion Biotech Opportunities Corp. Class A Ordinary Share position as of Q1 2022 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 2 Orion Biotech Opportunities Corp. Class A Ordinary Share shares in Q1 2022.
  • Tower Research Capital (TRC) first reported a position in Orion Biotech Opportunities Corp. Class A Ordinary Share in Q4 2021 and held it in 1 quarter.
  • Tower Research Capital (TRC)'s Orion Biotech Opportunities Corp. Class A Ordinary Share position peaked at $0 in Q4 2021.
  • 40 funds tracked by Wall St. Rank held Orion Biotech Opportunities Corp. Class A Ordinary Share as of Q1 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2022, filed 12 May 2022.